BOSTON—Monty Montoya has been named chief executive officer of TherOptix, a pre-clinical biopharma company focused on delivering clinically impactful therapeutics via a drug-eluding contact lens platform. TherOptix has received orphan drug designation on its lead candidate (001) for prevention of proliferative vitreoretinopathy (PVR). Monty has 30 years of experience in ophthalmology and most recently served as a founder and CEO of CorneaGen and founder of Aurion Biotech. Prior to CorneaGen, Monty served as CEO of SightLife, a global leader in cornea transplant.

“Having watched Monty grow mission-focused companies in multiple settings, I am elated to see him leading TherOptix and look forward to partnering with him and the rest of the team to see patients benefiting from this much-needed drug delivery system,” said Dick Lindstrom, MD, TherOptix board member and ophthalmology icon. 
“TherOptix is developing a novel ophthalmic drug delivery platform that has the potential to be a patient game-changer. I look forward to leading this great team through regulatory approval and commercialization,” said  Montoya. “TherOptix will offer patients the safest and most efficacious way for critical medicines to be delivered to the front and back of the eye,” he said.